Journey Medical (DERM)
Markets prescription dermatology medicines through a focused U.S. sales organization.
Something off on this page? Send us feedback.
Markets a U.S. portfolio of branded prescription dermatology medicines acquired through licenses and asset purchases. Its model couples product rights with a field-sales organization, while Emrosi was developed with Dr. Reddy’s Laboratories.
Builds and markets a U.S. portfolio of branded prescription dermatology medicines acquired through licenses and asset purchases. The marketed range includes Accutane, Qbrexza, Amzeeq, Zilxi and Emrosi, which was developed with Dr. Reddy’s Laboratories and is commercially promoted.
Sales rely on a field organization that reaches dermatologists across major U.S. metropolitan areas. Its sales-and-marketing model focuses on dermatology prescribers. The business is concentrated in the U.S. and depends on licensed or acquired product rights, FDA-approved prescription products and continued commercialization by its sales-and-marketing organization. Fortress Biotech retains voting control through Class A stock.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $25.6M · Total debt $25.5M · Total assets $98.4M · Shareholders' equity $32.1M
- Revenue
- $18.5M
- Operating income
- $456.0K
- Net income
- −$312.0K
No dividends on record.
| Institutions74 holders · as of Jun 30, 2026 | 37.95% | 10.71M shares | |
| Insiders9 holders · as of Jul 2, 2026 | 18.04% | 5.09M shares | |
| Strategic holders1 holder · as of May 31, 2024 | 34.94% | 9.86M shares | |
| Otherremainder | 9.07% | 2.56M shares |
28.22M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Fortress Biotech, Inc.1Strategic10 percent owner | 34.94% | 10.01M | 13Gfiled May 31, 2024 ↗ |
Wasatch Advisors LPInstitution | 10.13% | 2.86M | 13Fas of Jun 30, 2026 |
Claude MaraouiInsiderdirector, officer: President & CEO | 8.63% | 2.44M | Form 4filed Apr 24, 2026 ↗ |
Tang Capital Management LLCInstitution | 5.70% | 1.61M | 13Fas of Jun 30, 2026 |
Bryant R. RileyInsider | 3.33% | 939,695 | 13Gfiled Feb 11, 2022 ↗ |
| See all 25 → | |||
- Fortress Biotech, Inc.'s transaction reports restate only vehicles that traded; the 2022 ownership statement (10.01M) less the 150.0K net shares sold since is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Bausch Health
Prescription acne brands in topical dermatology
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Journey Medical | $7.85 | +0.90% | $213.8M | — | 38.4 | 3.1 | +23.3% |
| Bausch Health | $6.82 | −0.07% | $2.55B | — | 1.5 | 0.2 | +11.2% |
| Median | — | 1.5 | 0.2 | +11.2% |